The global primary biliary cholangitis therapeutics market size was estimated to be USD 0.742 billion in 2023 and is expected to reach USD 1.66 billion by 2034 with a CAGR of 7.61% during the forecast period 2024-2034. Rising primary biliary cholangitis cases, growing awareness of PBC, limited treatment options, development of new therapeutics, increasing healthcare spending, and favorable government policies will drive the market growth.
In the upcoming years, it is anticipated that global healthcare expenditure will increase, providing more funding for the creation and introduction of novel PBC therapies. Several variables, including aging populations, new diagnostic techniques, and environmental exposures, are contributing to this rising incidence. PBC is becoming more widely known to the general population and medical experts. The need for PBC therapies is being driven by the earlier diagnosis and treatment that results from this. For instance, Ocaliva with ursodeoxycholic acid (UDCA) was approved by the FDA in July 2023 by Intercept Pharmaceuticals to treat PBC in people who did not respond well to UDCA alone.
By type of treatment, the primary drugs segment accounted for the highest revenue-grossing segment in the global Primary Biliary Cholangitis Therapeutics market and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of microneedle technology for vaccine delivery, the convenience and painless administration it offers, as well as its potential to enhance vaccine efficacy and patient compliance. For instance, Ocaliva with ursodeoxycholic acid (UDCA) was approved by the FDA in July 2023 by Intercept Pharmaceuticals to treat PBC in people who did not respond well to UDCA alone.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global Primary Biliary Cholangitis Therapeutics market in 2023 owing to the increasing demand for convenient and on-site vaccination services, the well-established distribution network of hospital pharmacies, and the growing preference for healthcare professionals to administer microneedle flu vaccines in a controlled clinical setting. For instance, in November 2023, Genfit SA presented encouraging top-line data from the Phase 3 RESOLVE-IT research, which assessed elafibranor for the treatment of PBC. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing trend of digital healthcare services, increased consumer convenience, and the expanding reach of online platforms for pharmaceutical distribution.
North American region is anticipated for the highest revenue share during the forecast period owing to the robust healthcare infrastructure, widespread adoption of advanced medical technologies, and a high level of awareness among the population regarding preventive healthcare measures. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing population density, rising healthcare awareness, and ongoing efforts to strengthen healthcare infrastructure. The Asia Pacific region's anticipated fast growth in the forecast period is further driven by expanding government initiatives to improve vaccination coverage, a growing emphasis on preventive healthcare measures, and the increasing disposable income of the population, which enhances accessibility to healthcare services, including vaccination. For instance, in June 2023, CymaBay Therapeutics completed patient enrolment in the Phase 3 ALPINE-3 trial, which assessed Seladelpar's efficacy in treating PBC.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
In the upcoming years, it is anticipated that global healthcare expenditure will increase, providing more funding for the creation and introduction of novel PBC therapies. Several variables, including aging populations, new diagnostic techniques, and environmental exposures, are contributing to this rising incidence. PBC is becoming more widely known to the general population and medical experts. The need for PBC therapies is being driven by the earlier diagnosis and treatment that results from this. For instance, Ocaliva with ursodeoxycholic acid (UDCA) was approved by the FDA in July 2023 by Intercept Pharmaceuticals to treat PBC in people who did not respond well to UDCA alone.
By type of treatment, the primary drugs segment accounted for the highest revenue-grossing segment in the global Primary Biliary Cholangitis Therapeutics market and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of microneedle technology for vaccine delivery, the convenience and painless administration it offers, as well as its potential to enhance vaccine efficacy and patient compliance. For instance, Ocaliva with ursodeoxycholic acid (UDCA) was approved by the FDA in July 2023 by Intercept Pharmaceuticals to treat PBC in people who did not respond well to UDCA alone.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global Primary Biliary Cholangitis Therapeutics market in 2023 owing to the increasing demand for convenient and on-site vaccination services, the well-established distribution network of hospital pharmacies, and the growing preference for healthcare professionals to administer microneedle flu vaccines in a controlled clinical setting. For instance, in November 2023, Genfit SA presented encouraging top-line data from the Phase 3 RESOLVE-IT research, which assessed elafibranor for the treatment of PBC. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing trend of digital healthcare services, increased consumer convenience, and the expanding reach of online platforms for pharmaceutical distribution.
North American region is anticipated for the highest revenue share during the forecast period owing to the robust healthcare infrastructure, widespread adoption of advanced medical technologies, and a high level of awareness among the population regarding preventive healthcare measures. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing population density, rising healthcare awareness, and ongoing efforts to strengthen healthcare infrastructure. The Asia Pacific region's anticipated fast growth in the forecast period is further driven by expanding government initiatives to improve vaccination coverage, a growing emphasis on preventive healthcare measures, and the increasing disposable income of the population, which enhances accessibility to healthcare services, including vaccination. For instance, in June 2023, CymaBay Therapeutics completed patient enrolment in the Phase 3 ALPINE-3 trial, which assessed Seladelpar's efficacy in treating PBC.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type of Treatment, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Primary Biliary Cholangitis Therapeutics Market Report 2023 - 2034
Primary Biliary Cholangitis Therapeutics Market Analysis & Forecast by Type of Treatment 2023 - 2034 (Revenue USD Bn)
- Primary drugs
- Secondary drugs
- Liver Transplantation
Primary Biliary Cholangitis Therapeutics Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Primary Biliary Cholangitis Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Primary Biliary Cholangitis Therapeutics Market: Type of Treatment Estimates & Trend Analysis
8. Primary Biliary Cholangitis Therapeutics Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Primary Biliary Cholangitis Therapeutics Market
11. Europe Global Primary Biliary Cholangitis Therapeutics Market
12. Asia Pacific Global Primary Biliary Cholangitis Therapeutics Market
13. Latin America Global Primary Biliary Cholangitis Therapeutics Market
14. MEA Global Primary Biliary Cholangitis Therapeutics Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Intercept Pharmaceuticals
- Genfit SA
- CymaBay Therapeutics
- NGM Biopharmaceuticals
- Shire (now part of Takeda)
- GlaxoSmithKline plc
- Bristol Myers Squibb
- Pfizer Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Gilead Sciences Inc.
- Albireo Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Johnson & Johnson
- Zydus Cadila
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.74 Billion |
| Forecasted Market Value ( USD | $ 1.66 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
